US-based Regeneron Pharmaceuticals has completed its new US$115m headquarters and research facility in Tarrytown, New York.
The 21,000m2 facility comprises two buildings at real estate investment trust BioMed's The Landmark at Eastview life science campus.
"BioMed has provided the critical facilities and expertise that have effectively supported our expansion in Westchester County," said Leonard Schleifer. chief executive of Regeneron.
Biopharmaceutical company Regeneron develops medicines for the treatment of serious medical conditions including cancer, gout, and retinal and other diseases. It will use the new facilities for its r&d laboratories, clinical development staff, corporate headquarters and administrative offices.
BioMed Realty Trust is a real estate investment trust focused on providing property to the life science industry.
With the new buildings, Regeneron now occupies approximately 36,000m2 in four buildings on The Landmark campus. The company had four employees when it opened at The Landmark 20 years ago and now employs more than 1,000 people. The company's full-scale manufacturing facility is in Rensselaer, New York.
The new facilities offer environmentally friendly design features, including a white roof to reflect heat, a high efficiency HVAC system, building layouts for laboratories and offices to maximise day lighting, a courtyard located between buildings that maximises permeable surfaces to reduce water run-off, and extensive use of sustainable materials.